Nanoform and Boehringer Ingelheim execute master services agreement
Press release Nanoform Finland Plc August 3, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform and Boehringer Ingelheim execute master services agreement Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s award-winning CESS[®] technology can deliver to its drug development projects. The two parties have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development